Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 3, Issue , 2009, Pages 43-48

  Stevenson, M ^a   Scope, A ^b   Holmes, M ^b   Rees, A ^b   Kaltenthaler, E ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; MORPHOLINE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

ADULT; COST BENEFIT ANALYSIS; ECONOMICS; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; COST-BENEFIT ANALYSIS; HUMANS; MORPHOLINES; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; VENOUS THROMBOEMBOLISM;

MLCS; MLOWN;

EID: 84886943075     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl3/07     Document Type: Review

References (12)